Indication
Stereotactic Body Radiotherapy
4 clinical trials
2 products
2 drugs
Clinical trial
Phase I Study of Low Dose Radiotherapy and Concurrent SBRT in Combination With PD-1 Inhibitors in Advanced Non-small Cell Lung Cancer (NSCLC) .Status: Recruiting, Estimated PCD: 2025-06-30
Product
PD-1 InhibitorsClinical trial
A Retrospective Clinical Study of Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Carcinoma.Status: Completed, Estimated PCD: 2023-05-21
Clinical trial
Clinical Study of Stereotactic Body Radiotherapy Combined With Cadonilimab for the Treatment of Advanced Refractory Malignant Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2024-06-21
Drug
AK104Clinical trial
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With Stereotactic Body Radiotherapy for Hepatocellular Carcinoma Patients With Portal Vein Thrombosis.Status: Not yet recruiting, Estimated PCD: 2026-09-30